This Implementation Kit (I-Kit), developed by the Health Communication Capacity Collaborative (HC3), which is funded by USAID and based at the Johns Hopkins Center for Communication Programs, offers structured guidance for improving social and behavioural change communication (SBCC) strategies relat...ed to malaria in pregnancy (MiP). Designed for programme managers and stakeholders, the toolkit addresses critical communication gaps in MiP programming, particularly among service providers. It provides tools to help users integrate MiP into situation analyses, segment audiences, define behavioural objectives and draft strategic communication plans.
MiP poses a significant public health challenge, contributing to maternal and neonatal mortality and morbidity in sub-Saharan Africa. Although effective interventions exist, such as the use of insecticide-treated nets, intermittent preventive treatment in pregnancy (IPTp) and timely diagnosis and treatment, their implementation remains inconsistent. The I-Kit supports more effective SBCC planning and implementation, with the aim of increasing the uptake and impact of these interventions and ultimately reducing malaria-related deaths and illness among pregnant women and newborns.
more
This Implementation Kit (I-Kit), developed by the Health Communication Capacity Collaborative (HC3), helps national and local stakeholders to design country-specific social and behavioural change communication (SBCC) campaigns that address the threat posed by substandard, spurious, falsified and fal...sely labelled (SSFFC) malaria medicines. These poor-quality medicines endanger lives by failing to treat malaria effectively, undermine health systems, and contribute to drug resistance.
The I-Kit provides practical guidance and resources in six sections, including global examples, campaign design elements, media engagement strategies and tools for knowledge sharing. It is intended for health promotion officers, drug regulators, communication specialists and global health partners. Drawing heavily on experiences in Nigeria, the I-Kit promotes evidence-based, context-sensitive SBCC interventions to safeguard communities against SSFFC malaria medicines and enhance treatment outcomes.
more
Issued by the Ministers of Health of High Burden High Impact (HBHI) countries in Africa. Yaounde Declaration.
Ministers committed to strengthening their health systems, stepping up domestic resources, enhancing multisectoral action and ensuring a robust accountability mechanism,” notes Dr Daniel ...Ngamije, Director of the WHO Global Malaria Programme. “This is the kind of leadership the world must rally behind.
more
The Rwanda Malaria Strategic Plan 2020–2024 outlines Rwanda’s national strategy to reduce malaria morbidity and mortality by at least 50% compared to 2019 levels. The vision is a malaria-free Rwanda contributing to socioeconomic development.
The plan includes strengthening prevention through lo...ng-lasting insecticide-treated nets, indoor residual spraying, and larval source management; ensuring universal access to testing and treatment; improving surveillance and data use; and enhancing program management, coordination, and financing. It also emphasizes community engagement and behavior change to ensure at least 85% of the at-risk population adopts protective practices.
The strategy builds on past lessons, involves multi-sectoral collaboration, and aligns with global malaria goals. It highlights equity, quality services, and evidence-based interventions as guiding principles, aiming to mobilize national and international resources for sustained impact.
more
Standard Treatment Guideline
Standard Treatment Guideline
Bull World Health Organ 2015;93:457–467 | doi: http://dx.doi.org/10.2471/BLT.14.147215
Response to the tropical cyclone in southern Africa
Ebola virus disease outbreak in the Democratic Republic of the Congo
Meningitis outbreak in Togo
Lassa fever outbreak in Liberia.
The purpose of this document is to inform the public about biological and chemical hazards and thereby prepare the population for an immediate response in the event of an incident until public health support is provided.
The agents reported here are: Anthrax, Botulism, Haemorrhagic Fever,
...Smallpox, the Plague, Tularaemia, Chlorine, Cyanide, Lewisite, Mustard Gas,
Ricin, Sarin, Soman, Tabun and VX. This list is not exhaustive and no doubt
other dangerous types could be produced. They have been selected as they are the most often mentioned threats. This information has been prepared with the public in mind, and thus much of the medical terminology has been removed and replaced with every day language.
Also available in Arabic: http://www.who.int/csr/delibepidemics/biochem_threatsAR.pdf?ua=1
more
WHO estimates that in 2015, 257 million people were living with chronic hepatitis B virus (HBV) infection worldwide, and that 900 000 died from HBV infection, mostly through the development of cirrhosis and hepatocellular carcinoma. Worldwide, the majority of persons with chronic hepatitis B infecti...on and associated deaths in adulthood acquired their infection at birth through mother-to-child perinatal transmission or in early childhood.
more
The number of people facing acute food insecurity1 is growing at an alarming rate in the European Union (EU) Member States of Central Eastern Europe. COVID-19 and the resulting disruption to global markets, trade, and food supply chains have negatively affected food security since 2020; now, this ha...s been compounded by the Russian invasion of Ukraine. Women and girls who have been displaced from Ukraine into Hungary are facing tremendous obstacles to their safety and wellbeing, particularly given the link between food insecurity and gender-based violence (GBV). Urgent policy responses and concrete actions are needed to support low-income households and vulnerable communities, particularly women and their families displaced from Ukraine, to stem this growing crisis.
more
Resources for the Prevention and Treatment of Substance Use Disorders (SUD)
Technical Brief
HIV patient monitoring and case surveillance
WHO/HIV/2017.12
The report presents current information (updated to September 2015) on candidate vaccines, therapies and medical devices for Ebola and gives an overview of completed and on-going trials.